Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4Z7P

X-ray structure of racemic ShK Q16K toxin

Summary for 4Z7P
Entry DOI10.2210/pdb4z7p/pdb
Related4LFS
DescriptorPotassium channel toxin kappa-stichotoxin-She1a, SULFATE ION (3 entities in total)
Functional Keywordsshk toxin, toxin
Biological sourceStoichactis helianthus (Carribean sea anemone)
Cellular locationSecreted: P29187
Total number of polymer chains1
Total formula weight4551.26
Authors
Sickmier, E.A. (deposition date: 2015-04-07, release date: 2015-09-09, Last modification date: 2024-11-06)
Primary citationMurray, J.K.,Qian, Y.X.,Liu, B.,Elliott, R.,Aral, J.,Park, C.,Zhang, X.,Stenkilsson, M.,Salyers, K.,Rose, M.,Li, H.,Yu, S.,Andrews, K.L.,Colombero, A.,Werner, J.,Gaida, K.,Sickmier, E.A.,Miu, P.,Itano, A.,McGivern, J.,Gegg, C.V.,Sullivan, J.K.,Miranda, L.P.
Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.
J.Med.Chem., 58:6784-6802, 2015
Cited by
PubMed Abstract: To realize the medicinal potential of peptide toxins, naturally occurring disulfide-rich peptides, as ion channel antagonists, more efficient pharmaceutical optimization technologies must be developed. Here, we show that the therapeutic properties of multiple cysteine toxin peptides can be rapidly and substantially improved by combining direct chemical strategies with high-throughput electrophysiology. We applied whole-molecule, brute-force, structure-activity analoging to ShK, a peptide toxin from the sea anemone Stichodactyla helianthus that inhibits the voltage-gated potassium ion channel Kv1.3, to effectively discover critical structural changes for 15× selectivity against the closely related neuronal ion channel Kv1.1. Subsequent site-specific polymer conjugation resulted in an exquisitely selective Kv1.3 antagonist (>1000× over Kv1.1) with picomolar functional activity in whole blood and a pharmacokinetic profile suitable for weekly administration in primates. The pharmacological potential of the optimized toxin peptide was demonstrated by potent and sustained inhibition of cytokine secretion from T cells, a therapeutic target for autoimmune diseases, in cynomolgus monkeys.
PubMed: 26288216
DOI: 10.1021/acs.jmedchem.5b00495
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.2 Å)
Structure validation

237735

건을2025-06-18부터공개중

PDB statisticsPDBj update infoContact PDBjnumon